Development and validation of Hebrew version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument 2.0.
David J OzeriShani PeretzAmit OppenheimAbdallah WatadMerav LidarYolanda Braun-MoscoviciPublished in: Journal of scleroderma and related disorders (2022)
The translation of the Hebrew UCLA SCTC GIT 2.0 scale was reliable and valid with a total Cronbach's alpha score among the participants of 0.908. Cronbach's alpha was particularly reliable in reflux, bloating, social function, and emotional well-being. Our results suggest that our Hebrew version of the UCLA SCTC GIT 2.0 scale can be used as a tool in future studies with Hebrew-speaking patients. In the abstract conclusion, it states that "Cronbach's alpha was particularly reliable in reflux, bloating, social function, and emotional well-being." The related data should be listed in the results section and then an interpretation of the results should be listed in the conclusions section. Please revise.
Keyphrases
- clinical trial
- end stage renal disease
- healthcare
- mental health
- newly diagnosed
- chronic kidney disease
- ejection fraction
- systemic sclerosis
- patient reported outcomes
- psychometric properties
- open label
- current status
- electronic health record
- interstitial lung disease
- phase ii
- deep learning
- artificial intelligence
- case control
- phase iii